1 / 48

Immunology of Asthma through Biologics

Immunology of Asthma through Biologics. Jason Lee, MD, FRCPC. Private Practice & St Michael’s Hospital. Lecturer, Division of Clinical Immunology & Allergy Department of Medicine, University of Toronto. Learning Objectives. To understand the pathophysiologic basis of

ekram
Download Presentation

Immunology of Asthma through Biologics

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Immunology of Asthma through Biologics Jason Lee, MD, FRCPC Private Practice & St Michael’s Hospital Lecturer, Division of Clinical Immunology & Allergy Department of Medicine, University of Toronto

  2. Learning Objectives To understand the pathophysiologic basis of biologics in asthma To become familiar with various biologics that have been tried for asthma and the rationale behind these treatment approaches  learn the immunology

  3. Why the need for Biologics? Patientswith severe asthma who are uncontrolled with maximum doses of inhaled “conventional” therapies Although only 5% of all asthmatic patients are severe and these patients represent ~50% of health care spending Barnes, JACI. 2012 Biologics and asthma is a fascinating topic with a lot of exciting new advances

  4. Biologics are the future Current monoclonal antibodies are the fastest growing segment of the pharmaceutical industry • Albrecht H, Radosevich JA, Babich M. Fundamentals of antibody-related therapy and diagnostics. Drugs Today (Barc) 2009 Produced based on understanding the underlying immunology: -Cytokines -Monoclonal antibodies -Fusion proteins

  5. Why use Biologics? 1 2 Reduce the number of “collateral damage” thereby limiting side effects Easiest way to form a customized target medication

  6. What is happening?

  7. Healthy airway Smooth muscle

  8. Healthy airway Cells have no reaction to allergens

  9. With asthma Constricted airway during an asthma attack Mucus

  10. With asthma Cells see allergens as pathogens =

  11. Major Inflammatory Cells 1 2 Mast Cell Eosinophil

  12. Mast Cell Activation

  13. Role of IgE in Asthma Initially controversial IgE cross-linking leads to : - More IL4 - More CD40L on T cells - Induction of Eosinophilic inflammation = Even more IgE production In some asthma patients non-IgE mediated pathways that enhance Th2 cytokines

  14. - IgE not acting in Isolation. - Expression of FcεRIreceptor has been reported to be increased in fatal asthma FceRI receptor expression in lamina propria (+ cells/mm2) 1,085 * 1,200 1,000 800 600 400 200 0 Non-pulmonary deaths (n=9) Mild-intermittent asthma†(n=16) Fatal asthma (n=10) *p<0.05 vs other groups; †biopsy Fregonese L, et al. Am J RespirCrit Care Med 2004 (abstract)

  15. Eosinophil Activation

  16. Biologics used for asthma 1 2 Omalizumab Anti-il-5 mAbs

  17. Omalizumab

  18. Omalizumab significantly reduces severe exacerbations and emergency visits Severe exacerbation rate Total emergency visit rate ∆ –43.9% p=0.038 ∆ –50.0% p=0.002 0.6 0.5 0.4 0.3 0.2 0.1 0 0.6 0.5 0.4 0.3 0.2 0.1 0 Omalizumab(n=209) Placebo(n=210) Omalizumab(n=209) Placebo(n=210) Humbert M, et al. Allergy 2005

  19. Omalizumab significantly reducesthe need for systemic corticosteroid bursts Steroid bursts (mean) Relative risk: –43.0%p<0.001 0.8 0.6 0.4 0.2 0 Omalizumab (n=2,511) Control (n=1,797)) Maykut R, et al. J Allergy Clin Immunol 2006 (abstract) Busse W, et al. Curr Med Res Opin 2007;2379-2386

  20. OCS is reduced or stopped in 79% of patients following omalizumab therapy* Steroid bursts (mean) 78.8% Patients (%) 60 50 40 30 20 10 0 54.5 Reduced Stopped Not reduced/stopped Niven R, et al. Thorax 2007 (abstract)

  21. Anti-IL-5 mAbs

  22. Mepolizumab - Has been shown to reduce bronchial mucosa eosinophilia - In a subgroup: has clinical improvement or FEV1, BHR, peak flows - Reduces some extracellular matrix protein remodeling - 100% reduction in sputum eosinophils and airway eosinophils by 55%

  23. Future Therapies - TGF-B - Anti-IL-4 - Anti-IL-5 - Anti-IL-9 - Anti-IL-13 - Inhibition of Th2 cytokines - Inhaled anti-inflammatories targeting neutrophils - Novel classes of bronchodilators (Ro 25-1553, Rho kinase inhibitors - Targeting neutrophilic inflammatory mediators - Masitinib -> a tyrosine kinase inhibitor that blocks c-Kit - Cytokine receptor antagonists - TLR 4 and 9 agonists - Syk Kinase inhibitors - GATA3 antagonists

  24. Thank you! Q&A Jason Lee MD, FRCPC

More Related